Research graph
References from Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Local targets link to admitted publications; unresolved targets remain external evidence.
Shared decision making in endocrinology: present and future directions
10.1016/s2213-8587(15)00468-4 · 2016 · External reference
6. Glycemic targets: Standards of Medical Care in Diabetes—2022
10.2337/dc22-s006 · 2022 · External reference
Management of hyperglycaemia in type 2 diabetes: a patient-centred approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
10.1007/s00125-012-2534-0 · 2012 · External reference
Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes
10.1007/s00125-014-3460-0 · 2015 · External reference
Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
10.1007/s00125-018-4729-5 · 2018 · External reference
2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
10.1007/s00125-019-05039-w · 2020 · External reference
Development of the instrument to assess the credibility of effect modification analyses (ICEMAN) in randomized controlled trials and meta-analyses
10.1503/cmaj.200077 · 2020 · External reference
How to use a subgroup analysis: users’ guide to the medical literature
10.1001/jama.2013.285063 · 2014 · External reference
GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations
10.1016/j.jclinepi.2012.03.013 · 2013 · External reference
GRADE guidelines 26: informative statements to communicate the findings of systematic reviews of interventions
10.1016/j.jclinepi.2019.10.014 · 2020 · External reference
Reappraisal of the efficacy of intensive glycaemic control on microvascular complications in patients with type 2 diabetes: a meta-analysis of randomised control-trials
10.1016/j.therap.2021.10.002 · 2021 · External reference
Long-term follow-up of intensive glycaemic control on renal outcomes in the Veterans Affairs Diabetes Trial (VADT)
10.1007/s00125-017-4473-2 · 2018 · External reference
Historical HbA1c values may explain the type 2 diabetes legacy effect: UKPDS 88
10.2337/dc20-2439 · 2021 · External reference
A1C targets should be personalized to maximize benefits while limiting risks
10.2337/dci18-0018 · 2018 · External reference
Adults with early-onset type 2 diabetes (aged 18-39 years) are severely underrepresented in diabetes clinical research trials
10.1007/s00125-020-05174-9 · 2020 · External reference
9. Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes–2022
10.2337/dc22-s009 · 2022 · External reference
Intensive glycemic control and macrovascular, microvascular, hypoglycemia complications and mortality in older (age ≥60years) or frail adults with type 2 diabetes: a systematic review and meta-analysis from randomized controlled trial and observation studies
10.1080/17446651.2022.2079495 · 2022 · External reference
The use of language in diabetes care and education
10.2337/dci17-0041 · 2017 · External reference
Diabetes self-management education and support in adults with type 2 diabetes: a consensus report of the American Diabetes Association, the Association of Diabetes Care & Education Specialists, the Academy of Nutrition and Dietetics, the American Academy of Family Physicians, the American Academy of PAs, the American Association of Nurse Practitioners, and the American Pharmacists Association
10.2337/dci20-0023 · 2020 · External reference
2022 National standards for diabetes self-management education and support
10.2337/dc21-2396 · 2022 · External reference
Unresolved reference
External reference
5. Facilitating behavior change and well-being to improve health outcomes: Standards of Medical Care in Diabetes–2022
10.2337/dc22-s005 · 2022 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Diabetes self-management education for adults with type 2 diabetes mellitus: a systematic review of the effect on glycemic control
10.1016/j.pec.2015.11.003 · 2016 · External reference
Behavioral programs for type 2 diabetes mellitus: a systematic review and network meta-analysis
10.7326/m15-1400 · 2015 · External reference
Theory-based self-management educational interventions on patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials
10.1111/jan.13163 · 2017 · External reference
Effectiveness of group-based self-management education for individuals with type 2 diabetes: a systematic review with meta-analyses and meta-regression
10.1111/dme.13340 · 2017 · External reference
Diabetes self-management education reduces risk of all-cause mortality in type 2 diabetes patients: a systematic review and meta-analysis
10.1007/s12020-016-1168-2 · 2017 · External reference
Diabetes structured self-management education programmes: a narrative review and current innovations
10.1016/s2213-8587(17)30239-5 · 2018 · External reference
Supported self-management for people with type 2 diabetes: a meta-review of quantitative systematic reviews
10.1136/bmjopen-2018-024262 · 2018 · External reference
Prevalence of type 2 diabetes in psychiatric disorders: an umbrella review with meta-analysis of 245 observational studies from 32 systematic reviews
10.1007/s00125-021-05609-x · 2022 · External reference
Web-based interventions for dietary behavior in adults with type 2 diabetes: systematic review of randomized controlled trials
10.2196/16437 · 2020 · External reference
Impact of DSMES app interventions on medication adherence in type 2 diabetes mellitus: systematic review and meta-analysis
10.1136/bmjhci-2020-100291 · 2021 · External reference
The impact of a self-management educational program coordinated through WhatsApp on diabetes control
10.18549/pharmpract.2020.2.1841 · 2020 · External reference
Use of MyDesmond digital education programme to support self-management in people with type 2 diabetes during the COVID-19 pandemic
10.1111/dme.14469 · 2021 · External reference
Digital coaching strategies to facilitate behavioral change in type 2 diabetes: a systematic review
10.1210/clinem/dgaa850 · 2021 · External reference
A novel user utility score for diabetes management using tailored mobile coaching: secondary analysis of a randomized controlled trial
10.2196/17573 · 2021 · External reference
Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables
10.1016/s2213-8587(18)30051-2 · 2018 · External reference
Validation of the classification for type 2 diabetes into five subgroups: a report from the ORIGIN trial
10.1007/s00125-021-05567-4 · 2022 · External reference
1. Improving care and promoting health in populations: Standards of Medical Care in Diabetes–2022
10.2337/dc22-s001 · 2022 · External reference
What is shared decision making? (And what it is not)
10.1111/acem.13065 · 2016 · External reference
The design of a decision aid about diabetes medications for use during the consultation with patients with type 2 diabetes
10.1016/j.pec.2008.07.024 · 2008 · External reference
The diabetes mellitus medication choice decision aid: a randomized trial
10.1001/archinternmed.2009.293 · 2009 · External reference
Decision aids for people facing health treatment or screening decisions
2017 · External reference
The next generation of diabetes translation: a path to health equity
10.1146/annurev-publhealth-040218-044158 · 2019 · External reference
Social determinants of health and diabetes: a scientific review
10.2337/dci20-0053 · 2020 · External reference
Social determinants of health, race, and diabetes population health improvement: Black/African Americans as a population exemplar
10.1007/s11892-022-01454-3 · 2022 · External reference
Psychosocial care for people with diabetes: a position statement of the American Diabetes Association
10.2337/dc16-2053 · 2016 · External reference
Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation
10.1016/s0140-6736(21)01919-x · 2022 · External reference
Consensus report: definition and interpretation of remission in type 2 diabetes
10.2337/dci21-0034 · 2021 · External reference
2. Classification and diagnosis of diabetes: Standards of Medical Care in Diabetes—2022
10.2337/dc22-s002 · 2022 · External reference
7. Diabetes technology: Standards of Medical Care in Diabetes—2022
10.2337/dc22-s007 · 2022 · External reference
Effects of structured versus unstructured self-monitoring of blood glucose on glucose control in patients with non-insulin-treated type 2 diabetes: a meta-analysis of randomized controlled trials
10.1177/1932296817719290 · 2018 · External reference
Glucose self-monitoring in non-insulin-treated patients with type 2 diabetes in primary care settings: a randomized trial
10.1001/jamainternmed.2017.1233 · 2017 · External reference
Unresolved reference
External reference
Association of time in range, as assessed by continuous glucose monitoring, with diabetic retinopathy in type 2 diabetes
10.2337/dc18-1131 · 2018 · External reference
Longitudinal effects of medication nonadherence on glycemic control
10.1177/1060028014526362 · 2014 · External reference
Medication adherence in patients with diabetes mellitus: does physician drug dispensing enhance quality of care? Evidence from a large health claims database in Switzerland
10.2147/ppa.s115425 · 2016 · External reference
Meta-analysis of studies examining medication adherence, persistence, and discontinuation of oral antihyperglycemic agents in type 2 diabetes
10.1185/03007995.2015.1053048 · 2015 · External reference
Comparison of medication adherence and persistence in type 2 diabetes: A systematic review and meta-analysis
10.1111/dom.13160 · 2018 · External reference
Association between adherence to pharmacotherapy and outcomes in type 2 diabetes: a meta-analysis
10.2337/dc16-1925 · 2017 · External reference
Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors
10.2147/ppa.s106821 · 2016 · External reference
Barriers, facilitators, and interventions for medication adherence across chronic conditions with the highest non-adherence rates: a scoping review with recommendations for intervention development
2020 · External reference
Pen devices for insulin self-administration compared with needle and vial: systematic review of the literature and meta-analysis
10.1177/1932296816633721 · 2016 · External reference
Clinical inertia—time to reappraise the terminology?
10.1016/j.pcd.2017.01.007 · 2017 · External reference
Supporting insulin initiation in type 2 diabetes in primary care: results of the Stepping Up pragmatic cluster randomised controlled clinical trial
10.1136/bmj.j783 · 2017 · External reference
Overcoming clinical inertia in insulin initiation in primary care for patients with type 2 diabetes: 24-month follow-up of the Stepping Up cluster randomised controlled trial
10.1016/j.pcd.2017.06.005 · 2017 · External reference
The effect of nurse prescribers on glycaemic control in type 2 diabetes: a systematic review and meta-analysis
10.1016/j.ijnurstu.2017.08.018 · 2018 · External reference
Improving risk factor management for patients with poorly controlled type 2 diabetes: a systematic review of healthcare interventions in primary care and community settings
10.1136/bmjopen-2016-015135 · 2017 · External reference
Introduction: Standards of Medical Care in Diabetes—2022
10.2337/dc22-sint · 2022 · External reference
Effect of dietary carbohydrate restriction on glycemic control in adults with diabetes: a systematic review and meta-analysis
10.1016/j.diabres.2018.02.026 · 2018 · External reference
Systematic review and meta-analysis of dietary carbohydrate restriction in patients with type 2 diabetes
10.1136/bmjdrc-2016-000354 · 2017 · External reference
Effects of low-carbohydrate- compared with low-fat-diet interventions on metabolic control in people with type 2 diabetes: a systematic review including GRADE assessments
10.1093/ajcn/nqy096 · 2018 · External reference
A network meta-analysis on the comparative efficacy of different dietary approaches on glycaemic control in patients with type 2 diabetes mellitus
10.1007/s10654-017-0352-x · 2018 · External reference
The Mediterranean diet and cardiovascular health
10.1161/circresaha.118.313348 · 2019 · External reference
Primary prevention of cardiovascular disease with a Mediterranean diet supplemented with extra-virgin olive oil or nuts
10.1056/nejmoa1800389 · 2018 · External reference
Dietary patterns and management of type 2 diabetes: a systematic review of randomised clinical trials
10.1016/j.numecd.2019.02.004 · 2019 · External reference
Intermittent fasting versus continuous energy-restricted diet for patients with type 2 diabetes mellitus and metabolic syndrome for glycemic control: a systematic review and meta-analysis of randomized controlled trials
10.1016/j.diabres.2021.109003 · 2021 · External reference
Effect of intermittent compared with continuous energy restricted diet on glycemic control in patients with type 2 diabetes: a randomized noninferiority trial
10.1001/jamanetworkopen.2018.0756 · 2018 · External reference
The effect of intermittent compared with continuous energy restriction on glycaemic control in patients with type 2 diabetes: 24-month follow-up of a randomised noninferiority trial
10.1016/j.diabres.2019.03.022 · 2019 · External reference
Intermittent fasting in type 2 diabetes mellitus and the risk of hypoglycaemia: a randomized controlled trial
10.1111/dme.13595 · 2018 · External reference
Randomized controlled trial of a nationally available weight control program tailored for adults with type 2 diabetes
10.1002/oby.21616 · 2016 · External reference
Effects of nutrition therapy on HbA1c and cardiovascular disease risk factors in overweight and obese patients with type 2 diabetes
10.1186/s12937-018-0351-0 · 2018 · External reference
Structured lifestyle intervention based on a trans-cultural diabetes-specific nutrition algorithm (tDNA) in individuals with type 2 diabetes: a randomized controlled trial
10.1136/bmjdrc-2016-000384 · 2017 · External reference
Changes in dietary intake improve glycemic control following a structured nutrition therapy during Ramadan in individuals with type 2 diabetes
10.1016/j.clnesp.2021.09.738 · 2021 · External reference
Comparison of structured nutrition therapy for Ramadan with standard care in type 2 diabetes patients
10.3390/nu12030813 · 2020 · External reference
Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial
10.1016/s0140-6736(17)33102-1 · 2018 · External reference
Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial
10.1016/s2213-8587(19)30068-3 · 2019 · External reference
Does lifestyle intervention improve health of adults with overweight/obesity and type 2 diabetes? Findings from the Look AHEAD randomized trial
10.1002/oby.23158 · 2021 · External reference
Physical function following a long-term lifestyle intervention among middle aged and older adults with type 2 diabetes: the Look AHEAD study
10.1093/gerona/glx204 · 2018 · External reference
Long-term health benefits of intensive lifestyle intervention in the Look AHEAD study
10.1002/oby.23198 · 2021 · External reference
Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes
10.1056/nejmoa1212914 · 2013 · External reference
Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: a post-hoc analysis of the Look AHEAD randomised clinical trial
10.1016/s2213-8587(16)30162-0 · 2016 · External reference
Effects of intensive lifestyle intervention on all-cause mortality in older adults with type 2 diabetes and overweight/obesity: results from the Look AHEAD study
2022 · External reference
4. Comprehensive medical evaluation and assessment of comorbidities: Standards of Medical Care in Diabetes–2021
10.2337/dc21-s004 · 2021 · External reference
The impact of sleep amount and sleep quality on glycemic control in type 2 diabetes: a systematic review and meta-analysis
10.1016/j.smrv.2016.02.001 · 2017 · External reference
Sleep disorders in people with type 2 diabetes and associated health outcomes: a review of the literature
10.1007/s00125-021-05541-0 · 2021 · External reference
The impact of shift work on diabetes self-management activities
2019 · External reference
Physical behaviors and chronotype in people with type 2 diabetes
10.1136/bmjdrc-2020-001375 · 2020 · External reference
Exercise/physical activity in individuals with type 2 diabetes: a consensus statement from the American College of Sports Medicine
10.1249/mss.0000000000002800 · 2022 · External reference
World Health Organization 2020 guidelines on physical activity and sedentary behaviour
10.1136/bjsports-2020-102955 · 2020 · External reference
Frequency of interruptions to sitting time: benefits for postprandial metabolism in type 2 diabetes
10.2337/dc20-1410 · 2021 · External reference
Benefits for type 2 diabetes of interrupting prolonged sitting with brief bouts of light walking or simple resistance activities
10.2337/dc15-2336 · 2016 · External reference
Wrist-worn accelerometers: recommending ∼1.0 mg as the minimum clinically important difference (MCID) in daily average acceleration for inactive adults
10.1136/bjsports-2020-102293 · 2021 · External reference
Association between change in daily ambulatory activity and cardiovascular events in people with impaired glucose tolerance (NAVIGATOR trial): a cohort analysis
10.1016/s0140-6736(13)62061-9 · 2014 · External reference
Association of daily step count and step intensity with mortality among US adults
10.1001/jama.2020.1382 · 2020 · External reference
Dose-dependent effect of supervised aerobic exercise on HbA1c in patients with type 2 diabetes: a meta-analysis of randomized controlled trials
10.1007/s40279-022-01673-4 · 2022 · External reference
Physical activity, multimorbidity, and life expectancy: a UK Biobank longitudinal study
10.1186/s12916-019-1339-0 · 2019 · External reference
Exercise training modalities in patients with type 2 diabetes mellitus: a systematic review and network meta-analysis
10.1186/s12966-018-0703-3 · 2018 · External reference
Device-measured physical activity and its association with physical function in adults with type 2 diabetes mellitus
10.1111/dme.14393 · 2021 · External reference
Type 2 diabetes and impaired physical function: a growing problem
10.3390/diabetology3010003 · 2022 · External reference
Systematic review of clinical practice guidelines to identify recommendations for sleep in type 2 diabetes mellitus management
10.1016/j.diabres.2020.108532 · 2020 · External reference
Sleep regularity and cardiometabolic heath: is variability in sleep patterns a risk factor for excess adiposity and glycemic dysregulation?
10.1007/s11892-020-01324-w · 2020 · External reference
Unresolved reference
External reference
Prevalence of obstructive sleep apnea in patients with type 2 diabetes: a systematic review and meta-analysis
10.1016/j.dsx.2019.06.030 · 2019 · External reference
Effects of sleep manipulation on markers of insulin sensitivity: a systematic review and meta-analysis of randomized controlled trials
10.1016/j.smrv.2022.101594 · 2022 · External reference
The role of aerobic training variables progression on glycemic control of patients with type 2 diabetes: a systematic review with meta-analysis
10.1186/s40798-019-0194-z · 2019 · External reference
Effect of regular exercise training on changes in HbA1c, BMI and VO2max among patients with type 2 diabetes mellitus: an 8-year trial
10.1136/bmjdrc-2017-000414 · 2017 · External reference
The effects of postprandial exercise on glucose control in individuals with type 2 diabetes: a systematic review
10.1007/s40279-018-0864-x · 2018 · External reference
Effect of tai chi on glycaemic control, lipid metabolism and body composition in adults with type 2 diabetes: a meta-analysis and systematic review
10.2340/16501977-2799 · 2021 · External reference
Effectiveness of yoga-based exercise program compared to usual care, in improving HbA1c in individuals with type 2 diabetes: a randomized control trial
10.4103/ijoy.ijoy_33_20 · 2020 · External reference
Effect of high-intensity interval training protocols on VO2max and HbA1c level in people with type 2 diabetes: a systematic review and meta-analysis
10.1016/j.rehab.2021.101586 · 2022 · External reference
4. Comprehensive medical evaluation and assessment of comorbidities: Standards of Medical Care in Diabetes–2022
10.2337/dc22-s004 · 2022 · External reference
Effect of sleep extension on objectively assessed energy intake among adults with overweight in real-life settings: a randomized clinical trial
10.1001/jamainternmed.2021.8098 · 2022 · External reference
Ad libitum weekend recovery sleep fails to prevent metabolic dysregulation during a repeating pattern of insufficient sleep and weekend recovery sleep
10.1016/j.cub.2019.01.069 · 2019 · External reference
8. Obesity and weight management for the prevention and treatment of type 2 diabetes: Standards of Medical Care in Diabetes–2022
10.2337/dc22-s008 · 2022 · External reference
Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial
10.1016/s0140-6736(21)00213-0 · 2021 · External reference
Once-weekly semaglutide in adults with overweight or obesity
10.1056/nejmoa2032183 · 2021 · External reference
Tirzepatide once weekly for the treatment of obesity
10.1056/nejmoa2206038 · 2022 · External reference
Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial
10.1001/jama.2021.3224 · 2021 · External reference
Metabolic surgery in the treatment algorithm for type 2 diabetes: a joint statement by International Diabetes Organizations
10.2337/dc16-0236 · 2016 · External reference
Comparative effectiveness of bariatric surgeries in patients with type 2 diabetes mellitus and BMI ≥ 25 kg/m2: a systematic review and network meta-analysis
10.1007/s11695-021-05725-y · 2021 · External reference
Network meta-analysis of metabolic surgery procedures for the treatment of obesity and diabetes
10.1007/s11695-021-05643-z · 2021 · External reference
Metabolic surgery for the treatment of type 2 diabetes: a network meta-analysis of randomized controlled trials
10.1111/dom.14045 · 2020 · External reference
Does metabolic surgery lead to diabetes remission in patients with BMI < 30 kg/m2?: A meta-analysis
10.1007/s11695-018-03654-x · 2019 · External reference
Outcomes of bariatric surgery versus medical management for type 2 diabetes mellitus: a meta-analysis of randomized controlled trials
10.1007/s11695-018-3552-x · 2019 · External reference
Preoperative bariatric surgery predictors of type 2 diabetes remission
10.7570/jomes20084 · 2021 · External reference
Metabolic surgery versus conventional medical therapy in patients with type 2 diabetes: 10-year follow-up of an open-label, single-centre, randomised controlled trial
10.1016/s0140-6736(20)32649-0 · 2021 · External reference
Patient-reported outcomes after metabolic surgery versus medical therapy for diabetes: insights from the STAMPEDE randomized trial
10.1097/sla.0000000000005003 · 2021 · External reference
10. Cardiovascular disease and risk management: Standards of Medical Care in Diabetes–2022
10.2337/dc22-s010 · 2022 · External reference
Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis
10.1001/jamacardio.2020.4511 · 2021 · External reference
Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes
10.1056/nejmoa1504720 · 2015 · External reference
Canagliflozin and cardiovascular and renal events in type 2 diabetes
10.1056/nejmoa1611925 · 2017 · External reference
Dapagliflozin and cardiovascular outcomes in type 2 diabetes
10.1056/nejmoa1812389 · 2019 · External reference
Cardiovascular outcomes with ertugliflozin in type 2 diabetes
10.1056/nejmoa2004967 · 2020 · External reference
Sotagliflozin in patients with diabetes and chronic kidney disease
10.1056/nejmoa2030186 · 2021 · External reference
Dapagliflozin in patients with heart failure and reduced ejection fraction
10.1056/nejmoa1911303 · 2019 · External reference
Cardiovascular and renal outcomes with empagliflozin in heart failure
10.1056/nejmoa2022190 · 2020 · External reference
Sotagliflozin in patients with diabetes and recent worsening heart failure
10.1056/nejmoa2030183 · 2021 · External reference
Empagliflozin in heart failure with a preserved ejection fraction
10.1056/nejmoa2107038 · 2021 · External reference
Canagliflozin and renal outcomes in type 2 diabetes and nephropathy
10.1056/nejmoa1811744 · 2019 · External reference
Dapagliflozin in patients with chronic kidney disease
10.1056/nejmoa2024816 · 2020 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Euglycemic diabetic ketoacidosis caused by SGLT2 inhibitors and a ketogenic diet: a case series and review of literature
10.1016/j.aace.2020.11.009 · 2020 · External reference
Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial
10.1016/s2213-8587(21)00180-7 · 2021 · External reference
Association between combined treatment with SGLT2 inhibitors and metformin for type 2 diabetes mellitus on fracture risk: a meta-analysis of randomized controlled trials
10.1007/s00198-020-05590-y · 2020 · External reference
Sodium-glucose cotransporter 2 (SGLT-2) inhibitors and microvascular outcomes in patients with type 2 diabetes: systematic review and meta-analysis
10.1007/s40618-019-01103-9 · 2020 · External reference
Cardiovascular and renal outcomes with canagliflozin in patients with peripheral arterial disease: data from the CANVAS Program and CREDENCE trial
10.1111/dom.14671 · 2022 · External reference
Canagliflozin and kidney-related adverse events in type 2 diabetes and CKD: findings from the randomized CREDENCE trial
10.1053/j.ajkd.2021.05.005 · 2022 · External reference
GLP-1 receptor agonists in the treatment of type 2 diabetes–state-of-the-art
10.1016/j.molmet.2020.101102 · 2021 · External reference
Unresolved reference
External reference
Efficacy and safety of dulaglutide 3.0 mg and 4.5 mg versus dulaglutide 1.5 mg in metformin-treated patients with type 2 diabetes in a randomized controlled trial (AWARD-11)
10.2337/dc20-1473 · 2021 · External reference
Efficacy and safety of once-weekly semaglutide 2·0 mg versus 1·0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial
10.1016/s2213-8587(21)00174-1 · 2021 · External reference
Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice
10.1080/00325481.2021.2002616 · 2022 · External reference
Safety and tolerability of glucagon-like peptide-1 receptor agonists utilizing data from the exenatide clinical trial development program
10.1007/s11892-016-0728-4 · 2016 · External reference
Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy
10.1111/dom.13172 · 2018 · External reference
HbA1c change and diabetic retinopathy during GLP-1 receptor agonist cardiovascular outcome trials: a meta-analysis and meta-regression
10.2337/dc20-1815 · 2021 · External reference
Association of glucagon-like peptide-1 receptor agonist use with risk of gallbladder and biliary diseases: a systematic review and meta-analysis of randomized clinical trials
10.1001/jamainternmed.2022.0338 · 2022 · External reference
Effects of liraglutide on cardiovascular outcomes in type 2 diabetes patients with and without baseline metformin use: post hoc analyses of the LEADER trial
10.2337/dc20-0437 · 2020 · External reference
Sodium-glucose co-transporter-2 inhibitors with and without metformin: a meta-analysis of cardiovascular, kidney and mortality outcomes
10.1111/dom.14226 · 2021 · External reference
Novel antidiabetic drugs and risk of cardiovascular events in patients without baseline metformin use: a meta-analysis
10.1093/eurjpc/zwaa074 · 2021 · External reference
Insights from VERIFY: early combination therapy provides better glycaemic durability than a stepwise approach in newly diagnosed type 2 diabetes
10.1007/s13300-020-00926-7 · 2020 · External reference
Metformin treatment in patients with type 2 diabetes and chronic kidney disease stages 3A, 3B, or 4
10.2337/dc17-2231 · 2018 · External reference
Long-term treatment with metformin in type 2 diabetes and methylmalonic acid: post hoc analysis of a randomized controlled 4.3year trial
10.1016/j.jdiacomp.2017.11.001 · 2018 · External reference
Long-term metformin use and vitamin B12 deficiency in the Diabetes Prevention Program Outcomes Study
10.1210/jc.2015-3754 · 2016 · External reference
Effects of linagliptin on cardiovascular and kidney outcomes in people with normal and reduced kidney function: secondary analysis of the CARMELINA randomized trial
10.2337/dc20-0279 · 2020 · External reference
A randomized controlled study comparing a DPP4 inhibitor (linagliptin) and basal insulin (glargine) in patients with type 2 diabetes in long-term care and skilled nursing facilities: linagliptin-LTC trial
10.1016/j.jamda.2017.11.002 · 2018 · External reference
Comparison of glycemic variability and hypoglycemic events in hospitalized older adults treated with basal insulin plus vildagliptin and basal-bolus insulin regimen: a prospective randomized study
10.3390/jcm11102813 · 2022 · External reference
Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial
10.1016/s0140-6736(21)01324-6 · 2021 · External reference
Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial
10.1001/jama.2022.0078 · 2022 · External reference
Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes
10.1056/nejmoa2107519 · 2021 · External reference
Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial
10.1016/s0140-6736(21)01443-4 · 2021 · External reference
Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial
10.1016/s0140-6736(21)02188-7 · 2021 · External reference
Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial
10.1016/s2213-8587(22)00070-5 · 2022 · External reference
Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis
10.1007/s00125-022-05715-4 · 2022 · External reference
Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis
10.1038/s41591-022-01707-4 · 2022 · External reference
Do sulphonylureas still have a place in clinical practice?
10.1016/s2213-8587(18)30025-1 · 2018 · External reference
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
10.1016/s0140-6736(98)07019-6 · 1998 · External reference
Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial
10.1016/s2213-8587(17)30317-0 · 2017 · External reference
Effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: the CAROLINA randomized clinical trial
10.1001/jama.2019.13772 · 2019 · External reference
Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial
10.1001/jama.2018.18269 · 2019 · External reference
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
10.1056/nejmoa066224 · 2006 · External reference
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial
10.1016/s0140-6736(05)67528-9 · 2005 · External reference
Pioglitazone after ischemic stroke or transient ischemic attack
10.1056/nejmoa1506930 · 2016 · External reference
Pioglitazone therapy in patients with stroke and prediabetes: a post hoc analysis of the IRIS randomized clinical trial
10.1001/jamaneurol.2019.0079 · 2019 · External reference
Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial
10.7326/m15-1774 · 2016 · External reference
Pioglitazone even at low dosage improves NAFLD in type 2 diabetes: clinical and pathophysiological insights from a subgroup of the TOSCA.IT randomised trial
10.1016/j.diabres.2021.108984 · 2021 · External reference
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial
10.1016/s0140-6736(09)60953-3 · 2009 · External reference
One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes
10.2337/diacare.27.1.141 · 2004 · External reference
Pioglitazone and risk for bone fracture: safety data from a randomized clinical trial
2017 · External reference
Rosiglitazone-associated fractures in type 2 diabetes: an analysis from A Diabetes Outcome Progression Trial (ADOPT)
10.2337/dc07-2270 · 2008 · External reference
Pioglitazone: the forgotten, cost-effective cardioprotective drug for type 2 diabetes
10.1177/1479164118825376 · 2019 · External reference
Efficacy and safety of degludec versus glargine in type 2 diabetes
10.1056/nejmoa1615692 · 2017 · External reference
Basal insulin and cardiovascular and other outcomes in dysglycemia
10.1056/nejmoa1203858 · 2012 · External reference
Diabetes: how to manage patients experiencing hypoglycaemia
10.7573/dic.2021-9-11 · 2022 · External reference
Efficacy and safety of different basal and prandial insulin analogues for the treatment of type 2 diabetes: a network meta-analysis of randomized controlled trials
10.1007/s12020-021-02889-6 · 2021 · External reference
Inhaled insulin: a clinical and historical review
10.1097/crd.0000000000000143 · 2017 · External reference
Implementation of basal-bolus therapy in type 2 diabetes: a randomized controlled trial comparing bolus insulin delivery using an insulin patch with an insulin pen
10.1089/dia.2018.0298 · 2019 · External reference
Rethinking the viability and utility of inhaled insulin in clinical practice
10.1155/2018/4568903 · 2018 · External reference
Insulin/glucagon-like peptide-1 receptor agonist combination therapy for the treatment of type 2 diabetes: are two agents better than one?
10.2337/cd17-0065 · 2018 · External reference
Free and fixed-ratio combinations of basal insulin and GLP-1 receptor agonists versus basal insulin intensification in type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials
10.1111/dom.13343 · 2018 · External reference
Switching to iGlarLixi versus continuing daily or weekly GLP-1 RA in type 2 diabetes inadequately controlled by GLP-1 RA and oral antihyperglycemic therapy: the LixiLan-G randomized clinical trial
10.2337/dc19-1357 · 2019 · External reference
The efficacy of IDegLira (insulin degludec/liraglutide combination) in adults with type 2 diabetes inadequately controlled with a GLP-1 receptor agonist and oral therapy: DUAL III randomized clinical trial
10.1007/s13300-016-0218-3 · 2017 · External reference
Efficacy and safety of LixiLan, a titratable fixed-ratio combination of insulin glargine plus lixisenatide in type 2 diabetes inadequately controlled on basal insulin and metformin: the LixiLan-L randomized trial
10.2337/dc16-1495 · 2016 · External reference
Effect of insulin glargine up-titration vs insulin degludec/liraglutide on glycated hemoglobin levels in patients with uncontrolled type 2 diabetes: the DUAL V randomized clinical trial
10.1001/jama.2016.1252 · 2016 · External reference
Contribution of liraglutide in the fixed-ratio combination of insulin degludec and liraglutide (IDegLira)
10.2337/dc14-0785 · 2014 · External reference
Comparison of glycemic excursion using flash continuous glucose monitoring in patients with type 2 diabetes mellitus before and after treatment with voglibose
10.1089/dia.2019.0484 · 2021 · External reference
The role of GLP-1 in the postprandial effects of acarbose in type 2 diabetes
10.1530/eje-20-1121 · 2021 · External reference
Comparative effectiveness of glucose-lowering drugs for type 2 diabetes: a systematic review and network meta-analysis
10.7326/m20-0864 · 2020 · External reference
Comparative efficacy of glucose-lowering medications on body weight and blood pressure in patients with type 2 diabetes: a systematic review and network meta-analysis
10.1111/dom.14451 · 2021 · External reference
Durability of triple combination therapy versus stepwise addition therapy in patients with new-onset T2DM: 3-year follow-up of EDICT
10.2337/dc20-0978 · 2021 · External reference
Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial
10.1016/s0140-6736(19)32131-2 · 2019 · External reference
Durability of insulin degludec plus liraglutide versus insulin glargine U100 as initial injectable therapy in type 2 diabetes (DUAL VIII): a multicentre, open-label, phase 3b, randomised controlled trial
10.1016/s2213-8587(19)30184-6 · 2019 · External reference
Glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors as combination therapy for type 2 diabetes: a systematic review and meta-analysis
10.1111/dom.14108 · 2020 · External reference
The efficacy and safety of the combination therapy with GLP-1 receptor agonists and SGLT-2 inhibitors in type 2 diabetes mellitus: a systematic review and meta-analysis
10.3389/fphar.2022.838277 · 2022 · External reference
The efficacy and safety of combinations of SGLT2 inhibitors and GLP-1 receptor agonists in the treatment of type 2 diabetes or obese adults: a systematic review and meta-analysis
10.1007/s12020-019-02175-6 · 2020 · External reference
Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis
10.1016/s0140-6736(14)61335-0 · 2014 · External reference
SGLT2 inhibitor plus DPP-4 inhibitor as combination therapy for type 2 diabetes: a systematic review and meta-analysis
10.1111/dom.13294 · 2018 · External reference
Rationality, efficacy, tolerability of empagliflozin plus linagliptin combination for the management of type 2 diabetes mellitus: a systematic review of randomized controlled trials and observational studies
10.2174/1573399817666210910165402 · 2022 · External reference
Fixed-dose combination of empagliflozin and linagliptin for the treatment of patients with type 2 diabetes mellitus: a systematic review and meta-analysis
10.1111/dom.13989 · 2020 · External reference
Combination of sodium-glucose cotransporter 2 inhibitor and dipeptidyl peptidase-4 inhibitor in type 2 diabetes: a systematic review with meta-analysis
10.1038/s41598-018-22658-2 · 2018 · External reference
Combination therapy with an SGLT2 inhibitor as initial treatment for type 2 diabetes: a systematic review and meta-analysis
10.3390/jcm8010045 · 2019 · External reference
GLP-1 receptor agonist added to insulin versus basal-plus or basal-bolus insulin therapy in type 2 diabetes: a systematic review and meta-analysis
10.1002/dmrr.3082 · 2019 · External reference
Efficacy and safety of combination therapy with an α-glucosidase inhibitor and a dipeptidyl peptidase-4 inhibitor in patients with type 2 diabetes mellitus: a systematic review with meta-analysis
10.1111/jdi.12754 · 2018 · External reference
Efficacy and safety of initial combination therapy in treatment-naïve type 2 diabetes patients: a systematic review and meta-analysis
10.1007/s13300-018-0493-2 · 2018 · External reference
Risk of cardiovascular outcomes in patients with type 2 diabetes after addition of SGLT2 inhibitors versus sulfonylureas to baseline GLP-1RA Therapy
10.1161/circulationaha.120.047965 · 2021 · External reference
Efpeglenatide and clinical outcomes with and without concomitant sodium-glucose cotransporter-2 inhibition use in type 2 diabetes: exploratory analysis of the AMPLITUDE-O trial
10.1161/circulationaha.121.057934 · 2022 · External reference
Combination therapy with GLP-1 receptor agonist and SGLT2 inhibitor
10.1111/dom.12982 · 2017 · External reference
Primary prevention of cardiovascular and heart failure events with SGLT2 inhibitors, GLP-1 receptor agonists, and their combination in type 2 diabetes
10.2337/dc21-1113 · 2022 · External reference
Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial
10.1186/s12933-019-0942-x · 2019 · External reference
Glycemic outcomes in the glycemia reduction approaches in type 2 diabetes: a comparative effectiveness (GRADE) study
External reference
Glycemia reduction approaches in type 2 diabetes: a comparative effectiveness (GRADE) study microvascular and cardiovascular outcomes
External reference
Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes
10.1056/nejmoa2108269 · 2021 · External reference
Subcutaneous infusion of exenatide and cardiovascular outcomes in type 2 diabetes: a non-inferiority randomized controlled trial
10.1038/s41591-021-01584-3 · 2022 · External reference
Sodium-glucose co-transporter-2 inhibitors for the prevention of cardiorenal outcomes in type 2 diabetes: an updated meta-analysis
10.1111/dom.14374 · 2021 · External reference
Cardiovascular and mortality outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a meta-analysis with the FREEDOM cardiovascular outcomes trial
10.1016/j.dsx.2021.102382 · 2022 · External reference
Effect of the glucagon-like peptide-1 receptor agonists semaglutide and liraglutide on kidney outcomes in patients with type 2 diabetes: pooled analysis of SUSTAIN 6 and LEADER
10.1161/circulationaha.121.055459 · 2022 · External reference
SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis
10.1016/s2213-8587(19)30256-6 · 2019 · External reference
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials
10.1016/s2213-8587(21)00203-5 · 2021 · External reference
Effects of SGLT2 inhibitors on stroke and its subtypes in patients with type 2 diabetes: a systematic review and meta-analysis
10.1038/s41598-021-94945-4 · 2021 · External reference
Effects of semaglutide on stroke subtypes in type 2 diabetes: post hoc analysis of the randomized SUSTAIN 6 and PIONEER 6
10.1161/strokeaha.121.037775 · 2022 · External reference
GLP-1 receptor agonists for cardiovascular outcomes with and without metformin. A systematic review and meta-analysis of cardiovascular outcomes trials
10.1016/j.diabres.2021.108921 · 2021 · External reference
Glucagon-like peptide-1 receptor agonists and cardioprotective benefit in patients with type 2 diabetes without baseline metformin: a systematic review and update meta-analysis
10.1007/s40292-021-00479-1 · 2021 · External reference
Semaglutide reduces cardiovascular events regardless of metformin use: a post hoc subgroup analysis of SUSTAIN 6 and PIONEER 6
10.1186/s12933-022-01489-6 · 2022 · External reference
Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials
10.1136/bmj.m4573 · 2021 · External reference
The efficacy and safety of novel classes of glucose-lowering drugs for cardiovascular outcomes: a network meta-analysis of randomised clinical trials
10.1007/s00125-021-05529-w · 2021 · External reference
Sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 receptor agonists and the risk for cardiovascular outcomes in routine care patients with diabetes across categories of cardiovascular disease
10.7326/m21-0893 · 2021 · External reference
Diabetes mellitus correlates with increased biological age as indicated by clinical biomarkers
10.1007/s11357-021-00469-0 · 2022 · External reference
The impact of frailty on the effectiveness and safety of intensive glucose control and blood pressure-lowering therapy for people with type 2 diabetes: results from the ADVANCE trial
10.2337/dc20-2664 · 2021 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
GLP-1 receptor agonists and SGLT2 inhibitors for older people with type 2 diabetes: a systematic review and meta-analysis
10.1016/j.diabres.2021.108737 · 2021 · External reference
Prevalence of prediabetes among adolescents and young adults in the United States, 2005-2016
10.1001/jamapediatrics.2019.4498 · 2020 · External reference
Incidence of diabetes in youth in the United States
10.1001/jama.297.24.2716 · 2007 · External reference
Impact of insulin and metformin versus metformin alone on β-cell function in youth with impaired glucose tolerance or recently diagnosed type 2 diabetes
10.2337/dc18-0787 · 2018 · External reference
Lack of durable improvements in β-cell function following withdrawal of pharmacological interventions in adults with impaired glucose tolerance or recently diagnosed type 2 diabetes
10.2337/dc19-0556 · 2019 · External reference
The changing face of diabetes in youth: lessons learned from studies of type 2 diabetes
10.1111/nyas.12939 · 2015 · External reference
Effects of metformin, metformin plus rosiglitazone, and metformin plus lifestyle on insulin sensitivity and β-cell function in TODAY
10.2337/dc12-2393 · 2013 · External reference
Efficacy and safety of the addition of sitagliptin to treatment of youth with type 2 diabetes and inadequate glycemic control on metformin without or with insulin
10.1111/pedi.13282 · 2022 · External reference
Long-term complications in youth-onset type 2 diabetes
10.1056/nejmoa2100165 · 2021 · External reference
Resurgence in diabetes-related complications
10.1001/jama.2019.3471 · 2019 · External reference
Early combination therapy delayed treatment escalation in newly diagnosed young-onset type 2 diabetes: a subanalysis of the VERIFY study
10.1111/dom.14192 · 2021 · External reference
Association of sodium-glucose cotransporter 2 inhibitors with cardiovascular outcomes in patients with type 2 diabetes and other risk factors for cardiovascular disease: a meta-analysis
10.1001/jamanetworkopen.2021.42078 · 2022 · External reference
Do GLP-1RAs and SGLT-2is reduce cardiovascular events in black patients with type 2 diabetes? A systematic review and meta-analysis
10.1111/dom.13805 · 2019 · External reference
Unresolved reference
External reference
Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes
10.1007/pl00002934 · 2001 · External reference
Sex differences in the cardiovascular consequences of diabetes mellitus: a scientific statement from the American Heart Association
10.1161/cir.0000000000000343 · 2015 · External reference
Risk factors that attenuate the female coronary disease advantage
10.1001/archinte.1995.00430010063008 · 1995 · External reference
Sex differences in cardiovascular and total mortality among diabetic and non-diabetic individuals with or without history of myocardial infarction
10.1007/s00125-005-1730-6 · 2005 · External reference
Diabetes as a risk factor for stroke in women compared with men: a systematic review and meta-analysis of 64 cohorts, including 775,385 individuals and 12,539 strokes
10.1016/s0140-6736(14)60040-4 · 2014 · External reference
Diabetes as risk factor for incident coronary heart disease in women compared with men: a systematic review and meta-analysis of 64 cohorts including 858,507 individuals and 28,203 coronary events
10.1007/s00125-014-3260-6 · 2014 · External reference
Sex differences in the burden and complications of diabetes
10.1007/s11892-018-1005-5 · 2018 · External reference
Sex disparities in cardiovascular outcome trials of populations with diabetes: a systematic review and meta-analysis
10.2337/dc19-2257 · 2020 · External reference
Gender difference in cardiovascular outcomes with SGLT-2 inhibitors and GLP-1 receptor agonist in type 2 diabetes: a systematic review and meta-analysis of cardio-vascular outcome trials
10.1016/j.dsx.2020.02.012 · 2020 · External reference
Effects of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes in women versus men
10.1111/dom.13876 · 2020 · External reference
Advancing the global public health agenda for NAFLD: a consensus statement
10.1038/s41575-021-00523-4 · 2022 · External reference
Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease
10.1053/j.gastro.2021.07.049 · 2021 · External reference
A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis
10.1056/nejmoa2028395 · 2021 · External reference
Thiazolidinediones and advanced liver fibrosis in nonalcoholic steatohepatitis: a meta-analysis
10.1001/jamainternmed.2016.9607 · 2017 · External reference
Pioglitazone and bariatric surgery are the most effective treatments for non-alcoholic steatohepatitis: a hierarchical network meta-analysis
10.1111/dom.14304 · 2021 · External reference
Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: An updated systematic review of randomized controlled trials
10.1016/j.diabet.2019.12.007 · 2020 · External reference
Bariatric surgery provides long-term resolution of nonalcoholic steatohepatitis and regression of fibrosis
10.1053/j.gastro.2020.06.006 · 2020 · External reference
Insulin resistance is central to long-term reversal of histologic nonalcoholic steatohepatitis after metabolic surgery
10.1210/clinem/dgaa892 · 2021 · External reference
Effects of novel dual GIP and GLP-1 receptor agonist tirzepatide on biomarkers of nonalcoholic steatohepatitis in patients with type 2 diabetes
10.2337/dc19-1892 · 2020 · External reference
A meta-analysis of the effects of glucagon-like-peptide 1 receptor agonist (GLP1-RA) in nonalcoholic fatty liver disease (NAFLD) with type 2 diabetes (T2D)
10.1038/s41598-021-01663-y · 2021 · External reference
Effects of sodium-glucose co-transporter 2 inhibitors on liver parameters and steatosis: a meta-analysis of randomized clinical trials
10.1002/dmrr.3413 · 2021 · External reference
SGLT2 inhibitors for improving hepatic fibrosis and steatosis in non-alcoholic fatty liver disease complicated with type 2 diabetes mellitus: a systematic review
10.5114/ceh.2020.102173 · 2020 · External reference
SGLT2 inhibitors in patients with type 2 diabetes with non-alcoholic fatty liver diseases: an umbrella review of systematic reviews
10.1136/bmjdrc-2020-001956 · 2020 · External reference
Management of nonalcoholic fatty liver disease in patients with type 2 diabetes: a call to action
10.2337/dc16-1787 · 2017 · External reference
Ertugliflozin and incident obstructive sleep apnea: an analysis from the VERTIS CV trial
10.1007/s11325-022-02594-2 · 2022 · External reference
The impact of empagliflozin on obstructive sleep apnea and cardiovascular and renal outcomes: an exploratory analysis of the EMPA-REG OUTCOME trial
10.2337/dc20-1096 · 2020 · External reference
Team-based care to improve diabetes management: a community guide meta-analysis
10.1016/j.amepre.2019.02.005 · 2019 · External reference
Cardiovascular risk assessment scores for people with diabetes: a systematic review
10.1007/s00125-009-1454-0 · 2009 · External reference
Type 2 diabetes and cognitive dysfunction–towards effective management of both comorbidities
10.1016/s2213-8587(20)30118-2 · 2020 · External reference
Magnitude of cognitive dysfunction in adults with type 2 diabetes: a meta-analysis of six cognitive domains and the most frequently reported neuropsychological tests within domains
10.1017/s1355617713001483 · 2014 · External reference
Nutrition therapy for adults with diabetes or prediabetes: a consensus report
10.2337/dci19-0014 · 2019 · External reference
Unresolved reference
External reference
The Look AHEAD trial: a review and discussion of its outcomes
10.1007/s13668-014-0099-x · 2014 · External reference
Cardiovascular, renal, and metabolic outcomes of dapagliflozin versus placebo in a primary cardiovascular prevention cohort: analyses from DECLARE-TIMI 58
10.2337/dc20-2492 · 2021 · External reference
Liraglutide and cardiovascular outcomes in type 2 diabetes
10.1056/nejmoa1603827 · 2016 · External reference
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
10.1016/s0140-6736(19)31149-3 · 2019 · External reference
Effects of empagliflozin on markers of liver steatosis and fibrosis and their relationship to cardiorenal outcomes
10.1111/dom.14670 · 2022 · External reference
Microvascular disease and risk of cardiovascular events among individuals with type 2 diabetes: a population-level cohort study
10.1016/s2213-8587(16)30057-2 · 2016 · External reference
Efficacy and safety of antihyperglycaemic drug regimens added to metformin and sulphonylurea therapy in type 2 diabetes: a network meta-analysis
10.1111/dme.12837 · 2015 · External reference
Comparison of glucose-lowering agents after dual therapy failure in type 2 diabetes: a systematic review and network meta-analysis of randomized controlled trials
10.1111/dom.13185 · 2018 · External reference
Triple therapy in type 2 diabetes; a systematic review and network meta-analysis
10.7717/peerj.1461 · 2015 · External reference
Triple therapy combinations for the treatment of type 2 diabetes–a network meta-analysis
10.1016/j.diabres.2016.04.037 · 2016 · External reference
Efficacy and safety of vildagliptin in patients with type 2 diabetes mellitus inadequately controlled with dual combination of metformin and sulphonylurea
10.1111/dom.12229 · 2014 · External reference
Comparison of vildagliptin as an add-on therapy and sulfonylurea dose-increasing therapy in patients with inadequately controlled type 2 diabetes using metformin and sulfonylurea (VISUAL study): a randomized trial
10.1016/j.diabres.2015.04.019 · 2015 · External reference
A randomized controlled trial of the efficacy and safety of saxagliptin as add-on therapy in patients with type 2 diabetes and inadequate glycaemic control on metformin plus a sulphonylurea
10.1111/dom.12234 · 2014 · External reference
A randomized clinical trial evaluating the safety and efficacy of sitagliptin added to the combination of sulfonylurea and metformin in patients with type 2 diabetes mellitus and inadequate glycemic control
10.1111/1753-0407.12351 · 2016 · External reference
Unresolved reference
External reference
Comparative benefits and harms of basal insulin analogues for type 2 diabetes: a systematic review and network meta-analysis
10.7326/m18-0443 · 2018 · External reference
Addition of rapid-acting insulin to basal insulin therapy in type 2 diabetes: indications and modalities
10.1016/s1262-3636(07)70241-0 · 2006 · External reference
Rapid-acting insulin analogues versus regular human insulin: a meta-analysis of effects on glycemic control in patients with diabetes
10.1007/s13300-019-00732-w · 2020 · External reference
Lower rates of hypoglycemia during maintenance treatment with insulin degludec/insulin aspart versus biphasic insulin aspart 30: a combined analysis of two phase 3a studies in type 2 diabetes
10.1111/1753-0407.12355 · 2016 · External reference
Real-world clinical outcomes and costs in type 2 diabetes mellitus patients after initiation of insulin therapy: a German claims data analysis
10.1016/j.diabres.2021.108734 · 2021 · External reference
Efficacy and safety of basal insulin/GLP-1 receptor agonist used in combination for type 2 diabetes management
10.1177/0897190018764984 · 2019 · External reference
The effectiveness of telemedicine solutions for the management of type 2 diabetes: a systematic review, meta-analysis, and meta-regression
External reference
Effect of telemetric interventions on glycated hemoglobin A1c and management of type 2 diabetes mellitus: systematic meta-review
10.2196/23252 · 2021 · External reference
Impact of technology on glycaemic control in type 2 diabetes: A meta-analysis of randomized trials on continuous glucose monitoring and continuous subcutaneous insulin infusion
10.1111/dom.13845 · 2019 · External reference
The impact of flash glucose monitoring on glycaemic control as measured by HbA1c: a meta-analysis of clinical trials and real-world observational studies
10.1007/s13300-019-00720-0 · 2020 · External reference
Effect of continuous glucose monitoring on glycemic control in patients with type 2 diabetes treated with basal insulin: a randomized clinical trial
10.1001/jama.2021.7444 · 2021 · External reference
Unresolved reference
External reference
The Lancet Commission on diabetes: using data to transform diabetes care and patient lives
10.1016/s0140-6736(20)32374-6 · 2021 · External reference
Unresolved reference
External reference
IDF Diabetes Atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045
10.1016/j.diabres.2021.109119 · 2022 · External reference
Insulin discovery: a pivotal point in medical history
10.1016/j.metabol.2021.154941 · 2022 · External reference
A global perspective on the issue of access to insulin
10.1007/s00125-020-05375-2 · 2021 · External reference
Creating a learning health system through rapid-cycle, randomized testing
10.1056/nejmsb1900856 · 2019 · External reference
Advancing the learning health system
10.1056/nejmp2103872 · 2021 · External reference
Health information technology and digital innovation for national learning health and care systems
10.1016/s2589-7500(21)00005-4 · 2021 · External reference
